2. Search Result
Search Result
Results for "

enterococci

" in MedChemExpress (MCE) Product Catalog:

32

Inhibitors & Agonists

2

Biochemical Assay Reagents

4

Peptides

5

Natural
Products

3

Isotope-Labeled Compounds

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-P3078
    Amphomycin

    		Bacterial Antibiotic Infection
    Amphomycin is a lipopeptide antibiotic that inhibits peptidoglycan synthesis and blocks cell wall development. Amphomycin exhibits potent antibacterial activities against methicillin-resistant S. aureus (MRSA), vancomycin-resistant enterococci (VRE), penicillin-gentamicin-erythromycin-resistant S. pneumonia, and linezolid-quinupristin-dalfopristin-resistant enterococci .
    Amphomycin
  • HY-B1297
    Ceforanide

    		Antibiotic Bacterial Infection
    Ceforanide is a semisynthetic parental cephalosporin antibiotic, derived from 7-aminocephalosporanic acid. Ceforanide has antibacterial activity and is a potent inhibitor of most species of streptococci, excluding enterococci .
    Ceforanide
  • HY-10393
    Eperezolid

    PNU-100592

    		 Bacterial Antibiotic Infection
    Eperezolid (PNU-100592) is an orally active protein synthesis inhibitor that targets the bacterial 50S ribosomal subunit. Eperezolid competitively binds to a specific site on the ribosomal 50S subunit (overlapping with the binding sites of chloramphenicol (HY-B0239) and lincomycin (HY-117660)) to inhibit the translation initiation stage and exert antibacterial activity. Eperezolid can induce host cell autophagy to enhance the clearance of intracellular mycobacteria, and its MIC90 for Staphylococcus aureus and Enterococcus is 1-4 μg/mL. Eperezolid is mainly used for antibacterial research on infections with Gram-positive bacteria such as methicillin-resistant (HY-121544) Staphylococci and vancomycin-resistant (HY-B0671) Enterococci, as well as infections with intracellular bacteria such as Mycobacterium tuberculosis .
    Eperezolid
  • HY-14956
    Nemonoxacin
    1 Publications Verification

    TG-873870

    		 Antibiotic Bacterial Infection Inflammation/Immunology
    Nemonoxacin (TG-873870) is an orally active and potent broad-spectrum antibiotic. Nemonoxacin shows good inhibitory activity against different species of staphylococci, streptococci, and enterococci, Neisseria gonorrhoeae, and Haemophilus influenza. Nemonoxacin can be used in the study of bacterial infections and community-acquired pneumonia .
    Nemonoxacin
  • HY-Y1106
    Tripotassium phosphate

    		Environmental Pollutants Biochemical Assay Reagents Bacterial Infection
    Tripotassium phosphate is a Bactericid with bactericidal activity primarily against Gram-negative bacteria. Tripotassium phosphate reduces the population counts of Enterobacteriaceae and Campylobacter in poultry skin rinsates. Tripotassium phosphate fails to reduce the population count of Enterococcus in poultry skin rinsates .
    Tripotassium phosphate
  • HY-P11085
    WLBU2

    		Bacterial Infection
    WLBU2 is a engineered cationic antimicrobial peptide (eCAP) that overcomes the environmental sensitivity of natural antimicrobial peptides (AMPs). WLBU2 exhibits rapid bactericidal effect, with the MIC values of ≤ 10 μM against both Gram-negative and Gram-positive bacteria including MRSA, vancomycin-resistant enterococci, K. pneumoniae, E.aerogenes, E. cloacae, Escherichia coli, et, al. WLBU2 prevents P. aeruginosa biofilm growth and retains its activity in an environment rich in mucus, low pH and high salt concentrations without negative effects on human airway epithelial cells. WLBU2 can be used for the studies of cystic fibrosis (CF) and Pseudomonas aeruginosa infections .
    WLBU2
  • HY-125919
    Vulpinic acid

    		Reactive Oxygen Species (ROS) Bacterial Endogenous Metabolite Infection Inflammation/Immunology
    Vulpinic acid, a lichen metabolite, decreases H2O2-induced ROS production, oxidative stress and oxidative stress-related damages in human umbilical vein endothelial cells (HUVEC). Vulpinic acid is active against staphylococci, enterococci, and anaerobic bacteria.Vulpinic acid has the potential for atherosclerosis research .
    Vulpinic acid
  • HY-P5203
    Enterocin K1

    EntK1

    		 Bacterial Infection
    Enterocin K1 (EntK1) is a bacteriocin. Enterocin K1 is a ribosomal synthetic peptide. Enterocin K1 specifically targets Enterococcus faecalis via the Eep protein on the bacterial membrane. Enterocin K1 displays a potent antibacterial activity against VRE. Enterocin K1 can be used for related studies of VRE infections .
    Enterocin K1
  • HY-16137
    Cefaloglycin

    Cephaloglycin

    		 Bacterial Infection
    Cefaloglycin (Cephaloglycin) is an orally active nephrotoxic β-lactam cephalosporin antibiotic with antibacterial activity. Cefaloglycin is activity against Gram-Positive cocci other than enterococci. Cefaloglycin is toxic to mitochondrial substrate uptake and respiration .
    Cefaloglycin
  • HY-156198
    Bottromycin A2

    		Antibiotic Bacterial Infection
    Bottromycin A2 is a natural antibiotic. Bottromycin A2 is active against methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant Enterococci (VRE) .
    Bottromycin A2
  • HY-14956S
    Nemonoxacin-d3

    TG-873870-d3

    		 Bacterial Inflammation/Immunology
    Nemonoxacin-d3 is the deuterium labeled Nemonoxacin. Nemonoxacin (TG-873870) is an orally active and potent broad-spectrum antibiotic. Nemonoxacin shows good inhibitory activity against different species of staphylococci, streptococci, and enterococci, Neisseria gonorrhoeae, and Haemophilus influenza. Nemonoxacin can be used in the study of bacterial infections and community-acquired pneumonia .
    Nemonoxacin-d3
  • HY-116039
    Epiroprim

    Ro11-8958

    		 Dihydrofolate reductase (DHFR) Bacterial Infection
    Epiroprim (Ro11-8958) is a selective dihydrofolate reductase (DHFR) inhibitor. Epiroprim displays excellent activity against staphylococci, enterococci, pneumococci, and streptococci .
    Epiroprim
  • HY-W436428
    V-161

    		Na+/K+ ATPase Bacterial Infection
    V-161 is the orally active inhibitor for Na +-V-ATPase with an IC50 of 144 nM. V-161 inhibits Enterococcus hirae and Vancomycin-resistant Enterococcus faecium (VRE) under alkaline condition with MIC of 4 µg/mL and 4 µg/mL. V-161 inhibits colonization of VRE in mouse small intestine .
    V-161
  • HY-146811
    HSGN-94

    		Bacterial Inflammation/Immunology
    HSGN-94 is a potent antimicrobial agent with lipoteichoic acid (LTA) biosynthesis inhibition. HSGN-94 inhibits drug-resistant Gram-positive bacteria with MIC values of 0.25-2 μg/mL. HSGN-94 inhibits biofilm formation of MRSA and Vancomycin-resistant Enterococci. HSGN-94 also inhibits pro-inflammatory cytokines, exhibits in vivo efficacy in an MRSA murine wound infection model .
    HSGN-94
  • HY-117845
    Citreamicin alpha

    LL-E19085α

    		 Antibiotic Bacterial Infection
    Citreamicin alpha (LL-E 19085-alpha) is an antibiotic whose in vitro antimicrobial activity against 429 clinical isolates of Gram-positive cocci has been tested by the agar dilution method. These microorganisms included 313 strains of Staphylococci and 116 strains of Streptococci. The in vitro activity of Citreamicin alpha was compared with that of ampicillin, amoxicillin, ceftriaxone, erythromycin, and vancomycin. For Staphylococci, the MIC values of Citreamicin alpha ranged from 0.12-4.0 μg/ml, and for Streptococcus pyogenes of the genus Streptococcus, it was 0.03-0.12 μg/ml. However, enterococci were relatively resistant, requiring 2.0 μg/ml of the agent to inhibit 64% of the 62 tested strains. The in vitro activity of this antibiotic was much better than that of ampicillin, amoxicillin, ceftriaxone, and erythromycin, but comparable or slightly inferior to that of vancomycin.
    Citreamicin alpha
  • HY-105434
    CP-74667

    		Bacterial Infection
    CP-74667 is a quinolone antibacterial agent. CP-74667 shows high activity against Xanthomonas maltophilia (MIC50 = 1 μg/mL), Staphylococcus spp. (MIC50 = 0.06-0.12 μg/mL) and enterococci (MIC50 = 0.5-4 μg/mL) .
    CP-74667
  • HY-161935
    6-(12-Tridecene-1-yl)-2,4-Dihydroxy benzoic acid

    		Bacterial Infection Inflammation/Immunology
    6-(12-Tridecene-1-yl)-2,4-Dihydroxy benzoic acid (Compound 2) exhibits antibacterial activity against methicillin-resistant Staphylococcus aureus (MRSA) and Vancomycin enterococci (VRE). 6-(12-Tridecene-1-yl)-2,4-Dihydroxy benzoic acid interfers with the integrity and function of the bacterial cell membrane, and affects metabolism in MRSA. 6-(12-Tridecene-1-yl)-2,4-Dihydroxy benzoic acid exhibits anti-inflammatory and anti-infective efficacy, and promotes angiogenesis in mice .
    6-(12-Tridecene-1-yl)-2,4-Dihydroxy benzoic acid
  • HY-B1297R
    Ceforanide (Standard)

    		Reference Standards Antibiotic Bacterial Infection
    Ceforanide (Standard) is the analytical standard of Ceforanide. This product is intended for research and analytical applications. Ceforanide is a semisynthetic parental cephalosporin antibiotic, derived from 7-aminocephalosporanic acid. Ceforanide has antibacterial activity and is a potent inhibitor of most species of streptococci, excluding enterococci .
    Ceforanide (Standard)
  • HY-122174
    ME-1036

    CP-5609

    		 Antibiotic Bacterial Infection
    ME-1036 (CP-5609) is a carbapenem antibiotic. ME-1036 against resistant Gram-positive organisms, including Methicillin-resistant Staphylococcus aureus (MRSA), and vancomycin-resistant Enterococci (VRE), and ESBL-producing E. coli and K. pneumoniae but is not effective against P. aeruginosa .
    ME-1036
  • HY-14956S1
    Nemonoxacin-d3-1

    TG-873870-d3-1

    		 Bacterial Inflammation/Immunology
    Nemonoxacin-d3-1 is the deuterium labeled Nemonoxacin. Nemonoxacin (TG-873870) is an orally active and potent broad-spectrum antibiotic. Nemonoxacin shows good inhibitory activity against different species of staphylococci, streptococci, and enterococci, Neisseria gonorrhoeae, and Haemophilus influenza. Nemonoxacin can be used in the study of bacterial infections and community-acquired pneumonia .
    Nemonoxacin-d3-1
  • HY-14956S2
    Nemonoxacin-d4

    TG-873870-d4

    		 Bacterial Inflammation/Immunology
    Nemonoxacin-d4 is the deuterium labeled Nemonoxacin. Nemonoxacin (TG-873870) is an orally active and potent broad-spectrum antibiotic. Nemonoxacin shows good inhibitory activity against different species of staphylococci, streptococci, and enterococci, Neisseria gonorrhoeae, and Haemophilus influenza. Nemonoxacin can be used in the study of bacterial infections and community-acquired pneumonia .
    Nemonoxacin-d4
  • HY-W773487
    FtsZ-IN-10

    		Bacterial Infection
    FtsZ-IN-10 is a bacterial division inhibitor that interferes with the normal assembly of FtsZ. FtsZ-IN-10 specifically binds to Bacillus subtilis FtsZ monomers, thereby affecting their polymerization behavior. FtsZ-IN-10 may also activate nucleotide-free archaeal FtsZ to form ordered polymers. FtsZ-IN-10 can hinder the localization of FtsZ in the Z ring and inhibit bacterial cell division. Chlorinated analogs of FtsZ-IN-10 show the ability to inhibit the growth of antibiotic-resistant clinical isolates such as Staphylococcus aureus and Enterococci .
    FtsZ-IN-10
  • HY-113703
    PD117588

    		Antibiotic Cancer
    PD117588 is a quinolone antibacterial agent with a broad range of antibacterial activity. PD117588 exhibits excellent activity against a variety of Gram-positive and Gram-negative bacteria from cancer patients, especially against all Gram-positive strains, including methicillin-resistant Staphylococcus aureus, coagulase-negative Staphylococci, and Enterococci. PD117588 is also very effective against most Gram-negative bacilli, although ciprofloxacin shows stronger activity against Pseudomonas aeruginosa. Compared with other quinolone antibiotics, the minimum inhibitory concentration of PD117588 outperforms most of the tested microorganisms, including imipenem and ceftazidime .
    PD117588
  • HY-117247
    5,6,7,8-Tetrahydro-8-deazahomofolic acid

    		DNA/RNA Synthesis Infection
    5,6,7,8-Tetrahydro-8-deazahomofolic acid is a potential thymidylate synthase (TS) inhibitor with inhibitory activity against other folate-related enzymes. 5,6,7,8-Tetrahydro-8-deazahomofolic acid showed mild growth inhibition against enterococci, lactic acid bacteria, and L1210 cells in culture. 5,6,7,8-Tetrahydro-8-deazahomofolic acid also showed weak inhibition against thymidylate synthase, dihydrofolate reductase, glycyl-ribonucleoside aminotransferase, and aminoimidazole-carboxyacyl-ribonucleoside aminotransferase. 5,6,7,8-Tetrahydro-8-deazahomofolic acid showed low substrate activity for thymidylate synthase .
    5,6,7,8-Tetrahydro-8-deazahomofolic acid
  • HY-12770R
    Mebeverine alcohol (Standard)

    Mebeverine metabolite Mebeverine alcohol (Standard)

    		 Reference Standards Drug Metabolite Neurological Disease
    Mebeverine alcohol (Standard) is an analytical standard for Mebeverine alcohol. This product is intended for research and analytical applications. Eperezolid (PNU-100592) is an orally active protein synthesis inhibitor that targets the bacterial 50S ribosomal subunit. Eperezolid competitively binds to a specific site on the ribosomal 50S subunit (overlapping with the binding sites of Chloramphenicol (HY-B0239) and Lincomycin (HY-117660)) to inhibit the translation initiation stage and exert antibacterial activity. Eperezolid can induce host cell autophagy to enhance the clearance of intracellular mycobacteria, and its MIC90 for Staphylococcus aureus and Enterococcus is 1-4 μg/mL. Eperezolid is mainly used for antibacterial research on infections with Gram-positive bacteria such as methicillin-resistant (HY-121544) Staphylococci and vancomycin-resistant (HY-B0671) Enterococci, as well as infections with intracellular bacteria such as Mycobacterium tuberculosis .
    Mebeverine alcohol (Standard)
  • HY-181671
    Antibacterial agent 324

    		Bacterial Infection
    Antibacterial agent 324 is an amphipathic antibacterial agent. Antibacterial agent 324 exhibits selective activity against Gram-positive bacteria, with limited activity against enterococci and weak activity against Gram-negative bacteria .
    Antibacterial agent 324
  • HY-P11085A
    WLBU2 acetate

    		Bacterial Infection
    WLBU2 acetate is a engineered cationic antimicrobial peptide (eCAP) that overcomes the environmental sensitivity of natural antimicrobial peptides (AMPs). WLBU2 acetate exhibits rapid bactericidal effect, with the MIC values of ≤ 10 μM against both Gram-negative and Gram-positive bacteria including MRSA, vancomycin-resistant enterococci, K. pneumoniae, E.aerogenes, E. cloacae, Escherichia coli, et, al. WLBU2 acetate prevents P. aeruginosa biofilm growth and retains its activity in an environment rich in mucus, low pH and high salt concentrations without negative effects on human airway epithelial cells. WLBU2 acetate can be used for the studies of cystic fibrosis (CF) and Pseudomonas aeruginosa infections .
    WLBU2 acetate
  • HY-165460
    AM-112

    		Antibiotic Beta-lactamase Bacterial Penicillin-binding protein (PBP) Infection
    AM-112 is a β-lactamase (β-lactamase) inhibitor and antibacterial agent, with IC50 values ranging from 0.0002 μg/mL to 0.67 μg/mL against class A, C, and D β-lactamase. By inhibiting PBP2, the penicillin-binding protein of E. coli, and protecting Ceftazidime (HY-B0593) from enzymatic hydrolysis, AM-112 significantly enhances the antibacterial efficacy of Ceftazidime against Gram-negative bacteria, enterococci, and staphylococci. AM-112 exhibits favorable pharmacokinetic properties and acid-base stability. AM-112 can be used for the research of bacterial infections .
    AM-112
  • HY-69174
    1-Amino-2,5-anhydro-1-deoxy-D-mannitol

    		Bacterial
    1-Amino-2,5-anhydro-1-deoxy-D-mannitol is a potent antibacterial compound with antibacterial activity against a variety of Gram-positive bacteria, including methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant Enterococci (VRE). The application potential of 1-Amino-2,5-anhydro-1-deoxy-D-mannitol lies in its ability to effectively combat common drug-resistant bacterial infections. 1-Amino-2,5-anhydro-1-deoxy-D-mannitol may become an emerging antibacterial agent in clinical inhibition.
    1-Amino-2,5-anhydro-1-deoxy-D-mannitol
  • HY-180542
    CAI0019

    		Carbonic Anhydrase Bacterial Drug Derivative Infection
    CAI0019 is an orally active α-carbonic anhydrase inhibitor based on the Acetazolamide (HY-B0782) framework. CAI0019 exhibits narrow-spectrum antibiofilm activity, with its MIC50 being 0.094 μM and MIC90 being 0.39 μM. CAI0019 selectively inhibits Enterococcus in a septic peritonitis mouse model, without affecting most intestinal commensal bacteria .
    CAI0019
  • HY-181264
    Antifungal agent 153

    		Infection
    Antifungal agent 153, a derivative of Blasticidin S (HY-103401A), is an antibacterial agent. Antifungal agent 153 retains the antibacterial activity of Blasticidin S, exhibits potent inhibitory effects against multidrug-resistant Gram-positive bacteria, and significantly reduces mammalian cytotoxicity. Antifungal agent 153 can be used in studies related to bacterial infections .
    Antifungal agent 153
  • HY-N19290
    Glenthmycin E

    		Bacterial Infection
    Glenthmycin E is an antibacterial agent found in Australian sheep pasture-derived Streptomyces sp. CMB-PB041. Glenthmycin E inhibits growth of multiple bacterial and exhibits no detectable cytotoxicity to eukaryotic cells including fungal and human carcinoma cells. Glenthmycin E can be used for the research of bacterial infections .
    Glenthmycin E

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: